CURRENT MORBIDITY, MORTALITY, AND SURVIVAL AFTER BRONCHOPLASTIC PROCEDURES FOR MALIGNANCY
CURRENT MORBIDITY, MORTALITY, AND SURVIVAL AFTER BRONCHOPLASTIC PROCEDURES FOR MALIGNANCY
复制标题
DOI：
10.1016/0003-4975(92)91413-4
复制
发表时间：
1992-08-01
影响因子：
4.6
通讯作者：
LOWE, JE
中科院分区：
文献类型：
--
作者：
TEDDER, M;ANSTADT, MP;LOWE, JE
据报道，在过去十年中，接受支气管成形术的患者数量增加了近四倍。 这些技术代表了对良性支气管内病变、创伤性气道中断或低度恶性肿瘤患者以及可手术切除的肺癌患者的良好手术治疗。 89%的支气管成形术是针对恶性肿瘤进行的。 我们回顾了过去12年报道的1,915例肺癌支气管成形术，以确定并发症的发生率和生存率。 并发症包括局部复发（10.3%）、30天死亡率（7.5%）、肺炎（6.7%）、肺不张（5.4%）、良性狭窄或狭窄（5.0%）、支气管胸膜瘘（3.5%）、脓胸（2.8%）、支气管血管瘘（2.6%）和肺栓塞（1.9%）。 结果进一步分为袖状肺叶切除术组和袖状肺切除术组。 I期、II期和III期癌的5年生存率分别为63%、37%和21%。 袖状肺叶切除术扩大了手术治疗范围，选择的患者并发症发生率与肺切除术相当，长期生存率与传统切除术相似。
The number of patients reported to have undergone bronchoplastic procedures has increased nearly fourfold in the past decade. These techniques represent excellent surgical therapy for patients with benign endobronchial lesions, traumatic airway disruptions, or tumors of low-grade malignant potential, and for select patients with surgically resectable lung cancer. Eighty-nine percent of bronchoplastic procedures are performed for malignancy. We reviewed 1,915 bronchoplastic procedures for carcinoma reported over the past 12 years to determine the incidence of complications and survival. Complications included local recurrence (10.3%), 30-day mortality (7.5%), pneumonia (6.7%), atelectasis (5.4%), benign stricture or stenosis (5.0%), bronchopleural fistulas (3.5%), empyema (2.8%), bronchovascular fistulas (2.6%), and pulmonary embolism (1.9%). Results were further stratified into sleeve lobectomy and sleeve pneumonectomy groups. Five-year survivals for stage I, II, and III carcinoma were 63%, 37%, and 21%, respectively. Sleeve lobectomy for carcinoma extends surgical therapy to select patients with complication rates comparable to pneumonectomy and long-term survival similar to that for conventional resections.